Aurobindo Pharma Limited
NSE: AUROPHARMAMarket Closed • NSE
Day range
52 week range
Aurobindo Pharma Limited closed at INR1666.90 (-0.66%) on volume 0.91x its 20-day average, trading 4.2% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +12.1% QoQ
2026-04-17
BUYBACK Announced
Buy Back
2025-08-08
DIVIDEND Announced
Interim Dividend - Rs 4 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.21x
High Cash Flow Conversion: CFO/PAT averaged 1.58x over last 3 years
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 17 Apr 2026 | Buy Back | Buy Back | — | 17 Apr 2026 |
| 08 Aug 2025 | Dividend | ₹4.00 / share | — | 08 Aug 2025 |
| — | Annual General Meeting | Annual General Meeting | — | 26 Aug 2024 |
| 30 Jul 2024 | Buy Back | Buy Back | — | 30 Jul 2024 |
| 20 Feb 2024 | Dividend | ₹1.50 / share | — | 20 Feb 2024 |
| 20 Nov 2023 | Dividend | ₹3.00 / share | — | 20 Nov 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 22 Aug 2023 |
| 17 Feb 2023 | Dividend | ₹3.00 / share | — | 17 Feb 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 27 Jul 2022 |
| 07 Jun 2022 | Dividend | ₹4.50 / share | — | 06 Jun 2022 |
| 21 Feb 2022 | Dividend | ₹1.50 / share | — | 18 Feb 2022 |
| 18 Nov 2021 | Dividend | ₹1.50 / share | — | 17 Nov 2021 |
| 30 Aug 2021 | Dividend | ₹1.50 / share | — | 27 Aug 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 20 Aug 2021 |
| 23 Feb 2021 | Dividend | ₹1.50 / share | — | 22 Feb 2021 |
| 24 Nov 2020 | Dividend | ₹1.25 / share | — | 23 Nov 2020 |
| — | Dividend | ₹1.25 / share | — | 21 Aug 2020 |
| 18 Feb 2020 | Dividend | ₹1.75 / share | — | 17 Feb 2020 |
| 23 Nov 2019 | Dividend | ₹1.25 / share | — | 21 Nov 2019 |
| — | Annual General Meeting | Annual General Meeting | — | 21 Aug 2019 |
| 19 Feb 2019 | Dividend | ₹1.25 / share | — | 15 Feb 2019 |
| 22 Nov 2018 | Dividend | ₹1.25 / share | — | 20 Nov 2018 |
| — | Annual General Meeting | Annual General Meeting | — | 21 Aug 2018 |
| 21 Feb 2018 | Dividend | ₹1.00 / share | — | 20 Feb 2018 |
| 22 Nov 2017 | Dividend | ₹1.50 / share | — | 21 Nov 2017 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
IndiaHealthcare
Is Aurobindo Pharma Limited Shariah compliant?
Aurobindo Pharma Limited is currently screened as Non-Compliant (Financial Ratios) under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (2131%) exceeds AAOIFI threshold (≤ 33%).
What is Aurobindo Pharma Limited's current valuation relative to peers?
Aurobindo Pharma Limited trades at a P/E of 26.0x compared to the sector median of 37x, and a Price-to-Book of 2.6x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.21x. Interest coverage is comfortable.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 1.4% while net profit growth averaged 0.1%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.